Journal of Clinical Gastroenterology · 2002 · 42 citations · 17 references
PharmacyPharmacologyPharmacotherapyHepatic PharmacotherapyHepatologyVirologyAntiviral TherapyCirrhosisInterferon-based TherapyLiver DiseaseViral HepatitisViral Hepatitis TreatmentBiochemical Response AssessmentCirrhosis In Viral HepatitisHepatitis C InfectionHepatitis C Virus GenotypeInterferon Alfa TherapyRibavirin TherapySerum Alanine AminotransferaseViral Hepatitis-related Cirrhosis
BACKGROUND: Response to treatment with interferon alfa, with or without concomitant ribavirin, varies with the viral genotype and the degree of fibrosis in patients with chronic hepatitis C virus (HCV). GOALS: To determine the response of HCV type 4-related cirrhosis to interferon and ribavirin combination treatment compared with interferon alone. STUDY: Patients living in Kuwait were assigned to take either interferon alone at a dosage of 5 million units thrice weekly (26 patients) or interferon 5 million units thrice weekly combined with ribavirin 1,000 mg/d (21 patients) for 24 weeks. Biochemical response was defined as normal alanine aminotransferase (ALT) at end of therapy. Sustained biochemical response was defined as normal ALT 6 months after the end of therapy. Sustained virologic response was defined as negative serum HCV RNA 6 months after the end of therapy. RESULTS: Only 2 (8%) of 26 patients showed biochemical response after interferon alone, whereas 11 (52%) of 21 showed biochemical response after interferon combined with ribavirin (p < 0.01). Only 2 (8%) of 26 patients showed sustained biochemical response after interferon alone, whereas 5 (23%) of 21 showed sustained biochemical response after interferon combined with ribavirin (not significant, p > 0.1). None of the 26 patients showed virologic response after interferon alone, whereas 3 (14%) of 21 showed sustained virologic response after interferon combined with ribavirin (not significant, p > 0.1). CONCLUSION: These results suggest that patients with cirrhosis caused by HCV type 4 show no response to interferon alone and only slightly better response to 24 weeks of interferon combined with ribavirin.
17
Thierry Poynard, Patrick Marcellin, Samuel S. Lee et al. · The Lancet · 1998 · 2.3K citations
Ximing Xu, Guangjin Yuan, Qianwen Li et al. · Hepatogastroenterology · 2012 · 1.8K citations